Trending...
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
- Cal State LA secures funding for two artificial intelligence projects from CSU
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees.
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, December 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on The Californer
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
More on The Californer
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, December 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on The Californer
- Rachel Farris, CPA Featured on The AJ Brown Show to Discuss Act 60 Tax Incentives
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- Jade & Zelda Launch Virtually Human: A Groundbreaking Podcast Hosted by AI-Powered Virtual Humans
- Dr. Satyam Priyadarshy Joins Indemnify AI to Enrich AI Risk Financial Quantification
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
More on The Californer
- Fact: Trump lied — again. California gas prices remain lower than a week ago, month ago, and a year ago
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Top "We Buy Houses" Companies in Oakland, CA Announced — JiT Home Buyers Leads the Pack in 2025
- Ansira Appoints Amalia Thomas As Chief Revenue Officer
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Filed Under: Business
0 Comments
Latest on The Californer
- VoiceGenie AI empowers small businesses with 24/7, brand-driven customer engagement through an AI-powered virtual front desk receptionist
- California: Governor Newsom signs tribal-state gaming compact 7.14.25
- VoiceGenie AI empowers small businesses with human-like call answering and customer engagement—bridging the gap between automation and live
- New 24/7 AI solution transforms customer engagement and efficiency for small businesses seeking live virtual receptionist services
- Next-generation virtual receptionist service leverages AI to ensure every customer call and text is answered, enhancing efficiency and engagem
- Next-Gen AI Receptionist Elevates Customer Communication, Boosts Efficiency for Small Businesses
- California: Governor Newsom signs legislation 7.14.25
- New AI-Powered Platform from Kell Web Solutions Delivers 24/7 Professional, Automated Call Handling and Appointment Scheduling
- Kell Web Solutions Launches Next-Gen VoiceGenie AI Call Answering Service for Businesses
- 24/7 Conversational AI Platform Raises the Standard for Small Business Customer Engagement
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- QuickLogic Announces the Passing of Board Director Christine Russell
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- IEI USA Launches SHIELD Rugged Stainless Steel Panel PCs for Hygiene-Critical Industries
- In historic first, California powered by two-thirds clean energy – becoming largest economy in the world to achieve milestone
- North Island Credit Union Foundation Provides $5,000 in Teacher Grants To Benefit Educators & Students
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Wise Business Plans Emerges as a Go-To Partner for Angel Investors, VCs, Family Offices and Private
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science